Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies.

ABSTRACT: As many patients with underlying psychiatric disorders may be infected with COVID-19, and COVID-19-affected subjects may frequently experience a new onset of psychiatric manifestations, concomitant use of psychotropic medications and COVID-19 therapies is expected to be highly likely and raises concerns of clinically relevant drug interactions. In this setting, four major mechanisms responsible for drug interactions involving psychotropic agents and COVID-19 therapies may be identified: (1) pharmacokinetic drug-drug interactions mainly acting on cytochrome P450; (2) pharmacodynamic drug-drug interactions resulting in additive or synergistic toxicity; (3) drug-disease interactions according to stage and severity of the disease; and (4) pharmacogenetic issues associated with polymorphisms of

SUBMITTER: Gatti M 

PROVIDER: S-EPMC8053373 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature